CA*TX is a biotechnology company focused on cancer (CA) treatment (TX), especially developing novel treatments and diagnostics for CRC. The company was founded in 1993 by Dr Bruce M. Boman. 

The company’s current area of research involves development of an immunoassay for identification of HNPCC carriers that was funded by a Phase I SBIR grant and is now funded by a Phase II SBIR grant. Boman.